However, as the number of treated patients increases, some potential risks are emerging in the process of CD19 CAR-T-cell therapy, including aspects such as autologous cell collection and selection, gene vector selection, lymphodepletion regimens, posttreatment infection prophylaxis, and sequential bone marrow transplantation. The gene discussed is CD19; the disease is infection.